PMID-30919775 – Human Amylin From Pathology to Physiology and Pharmacology
Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: Pharmacology, Physiology, and Clinical Potential," Pharmacol Rev, 2015;67(3):564-600.
Quick Reference
| Property | Value |
|---|---|
| PMID | 30919775 |
| DOI | 10.1124/pr.115.010629 |
| Year | 2019 |
| Journal | Pharmacological Reviews |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | Amylin |
Key Findings
- Amylin receptor is a heteromeric complex of calcitonin receptor (CTR) + RAMP1/2/3, creating three distinct receptor subtypes (AMY1, AMY2, AMY3) with different tissue distributions
- Amylin's central satiety signal is mediated primarily through the area postrema (AP) in the brainstem — a circumventricular organ outside the BBB
- Amylin and leptin act synergistically to reduce food intake and body weight; amylin may restore leptin sensitivity in obese subjects
- Pramlintide (Symlin) demonstrated 1-2 kg weight loss as monotherapy and enhanced weight loss when combined with other agents
- Amylin analogs in development: cagrilintide (long-acting, ~1-week half-life via albumin binding + amino acid modifications), designed for once-weekly dosing
- Dual-agonist strategies (cagrilintide + semaglutide = CagriSema) show superior weight loss vs either component alone (up to 15-17% in Phase 2)
- Beyond metabolic effects: amylin has bone remodeling effects (inhibits osteoclasts via calcitonin receptor component), cardiovascular effects (vasodilation), and neuroprotective properties
Study Design
Comprehensive pharmacological review covering amylin receptor biology, signal transduction, physiological actions across organ systems, pathology in diabetes, and therapeutic development from pramlintide through next-generation long-acting analogs.
Limitations
- Review article; no new primary data
- Does not include Phase 3 CagriSema results (published subsequently)
- Some proposed clinical applications (bone effects, neuroprotection) remain preclinical
Clinical Relevance
This review is essential reading for understanding the pharmacological rationale behind cagrilintide (sold by Ageless Peps) and CagriSema (Novo Nordisk combination). The amylin-leptin synergy explains why cagrilintide adds meaningful weight loss when combined with GLP-1 agonists — they target complementary satiety pathways (amylin via area postrema, GLP-1 via NTS and hypothalamus). The long half-life engineering of cagrilintide vs native amylin (~15 min) demonstrates how peptide chemistry can transform a physiologically important but pharmacokinetically impractical hormone into a viable therapeutic.
Related
#research #narrative-review #evidence-level-V #metabolic #amylin #endogenous